C4X Discovery Holdings PLC
LSE:C4XD

Watchlist Manager
C4X Discovery Holdings PLC Logo
C4X Discovery Holdings PLC
LSE:C4XD
Watchlist
Price: 12 GBX 27.32% Market Closed
Market Cap: 30.3m GBX
Have any thoughts about
C4X Discovery Holdings PLC?
Write Note

C4X Discovery Holdings PLC
Net Issuance of Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

C4X Discovery Holdings PLC
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
C4X Discovery Holdings PLC
LSE:C4XD
Net Issuance of Common Stock
ÂŁ6k
CAGR 3-Years
-93%
CAGR 5-Years
-77%
CAGR 10-Years
N/A
Oxford Nanopore Technologies PLC
LSE:ONT
Net Issuance of Common Stock
ÂŁ71.6m
CAGR 3-Years
-24%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Diaceutics PLC
LSE:DXRX
Net Issuance of Common Stock
-ÂŁ49k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Genedrive PLC
LSE:GDR
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Ergomed PLC
LSE:ERGO
Net Issuance of Common Stock
ÂŁ305k
CAGR 3-Years
-46%
CAGR 5-Years
-46%
CAGR 10-Years
N/A
hVIVO PLC
LSE:HVO
Net Issuance of Common Stock
ÂŁ91k
CAGR 3-Years
-60%
CAGR 5-Years
-58%
CAGR 10-Years
-21%
No Stocks Found

C4X Discovery Holdings PLC
Glance View

Market Cap
30.3m GBX
Industry
Life Sciences Tools & Services

C4X Discovery Holdings Plc engages in the development of new technologies to improve the drug discovery process for novel small molecule therapies. The firm operates by early commercial partnering or initiation of a its drug discovery program to develop a small molecule. The firm also works in collaboration with partners. The firm has a portfolio ranging from early stage-target to late-stage drug discovery program ready for out-licensing to partners. The Company’s portfolio of pre-clinical small molecule candidates includes Oral NRF2 activator, Oral MALT1 inhibitor, Oral α4β7 integrin inhibitor, Oral Orexin-1 Antagonist (C4X_3256/INDV-2000), Oral IL-17A Inhibitor. The company has developed activators of the NRF2 pathway for the treatment of a variety of inflammatory diseases including Inflammatory Bowel Disease (IBD), Sickle Cell Disease (SCD), Pulmonary Arterial Hypertension (PAH) and Chronic Obstructive Pulmonary Disorder (COPD).

C4XD Intrinsic Value
43.44 GBX
Undervaluation 72%
Intrinsic Value
Price

See Also

What is C4X Discovery Holdings PLC's Net Issuance of Common Stock?
Net Issuance of Common Stock
6k GBP

Based on the financial report for Jan 31, 2024, C4X Discovery Holdings PLC's Net Issuance of Common Stock amounts to 6k GBP.

What is C4X Discovery Holdings PLC's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
-77%

Over the last year, the Net Issuance of Common Stock growth was -100%. The average annual Net Issuance of Common Stock growth rates for C4X Discovery Holdings PLC have been -93% over the past three years , -77% over the past five years .

Back to Top